• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/9/21 8:18:51 AM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $NTUS alert in real time by email
    SC 13G 1 natusmedical13g_123120.htm

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    ( Amendment No. )*

    Natus Medical Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    639050103

    (CUSIP Number) 

    December 31, 2020

    (Date of Event which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    x  Rule 13d-1(b)
    ¨  Rule 13d-1(c)
    ¨  Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

     

             
    CUSIP No. 639050103   13G   Page 2 of 4 Pages
             

     

             
    1.  

    NAMES OF REPORTING PERSONS

     

    Victory Capital Management Inc.


    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    13-2700161

       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨
       
    3.   SEC USE ONLY
     
       
    4.   CITIZENSHIP OR PLACE OF ORGANIZATION
     
    New York
       

     

             
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   5.  

    SOLE VOTING POWER
     
    2,009,623

      6.   SHARED VOTING POWER
     
    0
      7.   SOLE DISPOSITIVE POWER
     
    2,035,273
      8.   SHARED DISPOSITIVE POWER
     
    0

     

             
    9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,035,273
       
    10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨
       
    11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.01%
       
    12.   TYPE OF REPORTING PERSON (see instructions)

    IA
       
             
             
                     
     
     

     

             
    CUSIP No. 639050103   13G   Page 3 of 4 Pages
             

    Item 1.

      (a) Name of Issuer
    Natus Medical Inc.
         
      (b)

    Address of Issuer’s Principal Executive Offices

    6701 Koll Center Parkway Suite 120

    Pleasanton, CA 94566

         

    Item 2.

      (a) Name of Persons Filing
    Victory Capital Management Inc.
         
      (b)

    Address of the Principal Office or, if none, residence
    4900 Tiedeman Rd. 4th Floor

    Brooklyn, OH 44144

         
      (c) Citizenship
    New York
         
      (d) Title of Class of Securities
    Common Stock
         
      (e) CUSIP Number
    639050103
         

    Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(J).
           

    Item 4.  Ownership.

     
     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

             
      (a)   Amount beneficially owned:  2,035,173
             
      (b)   Percent of class:  6.01%
             
      (c)   Number of shares as to which the person has:
             
          (i)

    Sole power to vote or to direct the vote:  2,009,623

             
          (ii) Shared power to vote or to direct the vote:  0
             
          (iii) Sole power to dispose or to direct the disposition of:  2,035,173
             
          (iv)

    Shared power to dispose or to direct the disposition of:  0

    Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

             

    Item 5.  Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ¨

    Item 6.  Ownership of More than Five Percent on Behalf of Another Person.

    The clients of Victory Capital Management Inc., including investment companies registered under the Investment Company Act of 1940 and separately managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the class of securities reported herein. No client has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5% of such class.

     

    Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     Not applicable

    Item 8.  Identification and Classification of Members of the Group.

     Not applicable.

    Item 9.  Notice of Dissolution of Group.

     Not applicable.

    Item 10.  Certification.

           
      (a)   The following certification shall be included if the statement is filed pursuant to §240.13d-1(b):
             
          By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.  
             
             
     
     

     

             
    CUSIP No. 639050103   13G   Page 4 of 4 Pages
             

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    2/9/2021

    Date

     

    /s/ Colin S. Kinney

    Signature

     

    Colin S. Kinney / Chief Compliance Officer

    Name/Title

     

     

    Get the next $NTUS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NTUS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NTUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Schroeder Alice D. returned $750,601 worth of shares to the company (22,406 units at $33.50), closing all direct ownership in the company (for withholding tax)

    4 - NATUS MEDICAL INC (0000878526) (Issuer)

    7/21/22 5:25:24 PM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4: Moore Bryant M returned $338,819 worth of shares to the company (10,114 units at $33.50), closing all direct ownership in the company (withholding obligation)

    4 - NATUS MEDICAL INC (0000878526) (Issuer)

    7/21/22 5:22:51 PM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4: Levine Joshua returned $1,252,464 worth of shares to the company (37,387 units at $33.50), closing all direct ownership in the company to cover taxes

    4 - NATUS MEDICAL INC (0000878526) (Issuer)

    7/21/22 5:20:45 PM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NTUS
    SEC Filings

    View All

    SEC Form 15-12G filed by Natus Medical Incorporated

    15-12G - NATUS MEDICAL INC (0000878526) (Filer)

    8/1/22 4:09:00 PM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form EFFECT filed by Natus Medical Incorporated

    EFFECT - NATUS MEDICAL INC (0000878526) (Filer)

    7/25/22 12:15:44 AM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form EFFECT filed by Natus Medical Incorporated

    EFFECT - NATUS MEDICAL INC (0000878526) (Filer)

    7/25/22 12:15:29 AM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NTUS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Route 92 Medical Announces Appointment of Jonathan Kennedy as Chief Financial Officer

    SAN MATEO, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the appointment of Jonathan Kennedy to the role of Chief Financial Officer. In this role, Jonathan will be responsible for overseeing all financial management for the company, reporting directly to Chief Executive Officer Tony Chou. "Route 92 Medical's technology offers uniquely disruptive solutions in the rapidly growing stroke treatment market. The company is well-positioned for long-term growth, continued product innovation, and meaningful improvements in patient outc

    9/18/23 9:00:00 AM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Novanta Set to Join S&P MidCap 400; Six Flags Entertainment to Join S&P SmallCap 600

    NEW YORK, July 21, 2022 /PRNewswire/ -- Novanta Inc. (NASD: NOVT) will replace Six Flags Entertainment Corp. (NYSE:SIX) in the S&P MidCap 400, and Six Flags will replace Natus Medical Inc. (NASD: NTUS) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, July 26. ArchiMed acquired Natus Medical in a deal that closed today. Six Flags Entertainment is more representative of the small-cap market space. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector July 26, 2022 S&P MidCap 400 Addition Novanta NOVT Information Technology S&P MidCap 400

    7/21/22 6:36:00 PM ET
    $NOVT
    $NTUS
    $SIX
    Industrial Machinery/Components
    Miscellaneous
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    ArchiMed completes acquisition of Natus Medical Incorporated for $1.2 billion total equity value

    MIDDLETON, Wis., July 21, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the "Company" or "Natus"), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, announced today that the MED Platform II fund of ArchiMed ("ArchiMed"), a leading investment firm focused exclusively on the healthcare industry, completed the acquisition of Natus. In accordance with the definitive merger agreement, Natus shareholders received $33.50 in cash for each share of Natus common stock. "ArchiMed's mix of operational, medical, scientific and financial expertise will help us continue

    7/21/22 9:13:26 AM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NTUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Natus Medical Incorporated (Amendment)

    SC 13G/A - NATUS MEDICAL INC (0000878526) (Subject)

    2/2/22 9:06:01 AM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Natus Medical Incorporated

    SC 13G - NATUS MEDICAL INC (0000878526) (Subject)

    1/19/22 7:51:36 AM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - NATUS MEDICAL INC (0000878526) (Subject)

    2/10/21 11:28:21 AM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NTUS
    Financials

    Live finance-specific insights

    View All

    ArchiMed completes acquisition of Natus Medical Incorporated for $1.2 billion total equity value

    MIDDLETON, Wis., July 21, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the "Company" or "Natus"), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, announced today that the MED Platform II fund of ArchiMed ("ArchiMed"), a leading investment firm focused exclusively on the healthcare industry, completed the acquisition of Natus. In accordance with the definitive merger agreement, Natus shareholders received $33.50 in cash for each share of Natus common stock. "ArchiMed's mix of operational, medical, scientific and financial expertise will help us continue

    7/21/22 9:13:26 AM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Natus Medical Incorporated to be acquired by ArchiMed Group for $33.50 per share in cash

    Highlights: •        Transaction values Natus Medical, Incorporated at approximately $1.2 billion total equity value•        Pre-announces preliminary financial results for the first quarter ended March 31, 2022 MIDDLETON, Wis., April 18, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS), (the "Company" or "Natus"), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, announced today that it has entered into a definitive agreement to be acquired by an affiliate of ArchiMed ("ArchiMed"), a leading investment firm focused exclusively on the healthcare industry for app

    4/18/22 7:00:00 AM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Natus Medical to Hold 2022 First Quarter Financial Results Conference Call on May 6th

    PLEASANTON, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS), (the "Company" or "Natus"), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company will release its 2022 first quarter financial results after the close of the market on Thursday, May 5th. Natus management will host a conference call on Friday, May 6th at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to discuss those results and to answer questions. Individuals interested in listening to the conference call may do so by dialing 1-844-634-1441 for domes

    4/1/22 4:10:00 PM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NTUS
    Leadership Updates

    Live Leadership Updates

    View All

    Route 92 Medical Announces Appointment of Jonathan Kennedy as Chief Financial Officer

    SAN MATEO, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the appointment of Jonathan Kennedy to the role of Chief Financial Officer. In this role, Jonathan will be responsible for overseeing all financial management for the company, reporting directly to Chief Executive Officer Tony Chou. "Route 92 Medical's technology offers uniquely disruptive solutions in the rapidly growing stroke treatment market. The company is well-positioned for long-term growth, continued product innovation, and meaningful improvements in patient outc

    9/18/23 9:00:00 AM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Natus Medical Announces Executive Transition

    Thomas J. Sullivan Appointed President & Chief Executive Officer No Change To 4th Quarter Guidance PLEASANTON, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the "Company" or "Natus"), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced the appointment of Thomas J. Sullivan as President & Chief Executive Officer effective December 27, 2021 and a focus on long-term growth. Earlier this year, the Board of Directors engaged a strategic consulting firm to assist it in developing a strategy to build upon Natus' market leading p

    12/17/21 4:01:00 PM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care